|
Massachusetts Boston Cancer News is an EIN News Service for health professionals. Constantly updated news and information about Massachusetts Health.
Latest Massachusetts Boston Cancer News
- ImmunoGen Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma 18 Nov 2009 14:55 GMT
... Compound in the Treatment of Merkel Cell Carcinoma WALTHAM, MA, November 17, 2009 – ImmunoGen, ... IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with ... Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC ...
- Skin implant to fight cancer developed 26 Nov 2009 08:34 GMT
... An implant which inserts a cancer vaccine into the skin to destroy tumours ... Professor David Mooney, of Harvard University in Boston, said: "Inserted anywhere under the skin - ... implants activate an immune response that destroys tumour cells." The fingernail-size disks made of a ...
- New Markers of Prognosis for Cancer Therapies Highlighted 18 Nov 2009 20:52 GMT
... New Markers of Prognosis for Cancer Therapies Highlighted Newswise - Recent advances in ... 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ... and HER2 positive breast cancers, renal cell carcinoma and other advanced solid tumors. "This is ...
- Press conference highlights emerging treatments in pancreatic cancer 18 Nov 2009 09:58 GMT
... Pancreatic cancer remains one of the deadliest and hardest ... 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ... of delivering therapies, angiogenesis, microRNA and the tumor microenvironment. "Successful treatment of pancreatic cancer is ...
- Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conference 19 Nov 2009 06:33 GMT
... presents new research data on its innovative antitumor drug candidate BAL27862 at the international conference ... the international conference on Molecular Targets and Cancer Therapeutics in Boston (MA). BAL27862 is a novel, intravenous and ...
- Basilea presents new research data on oncology drug candidate BAL27862 at international cancer confe 19 Nov 2009 06:59 GMT
... on oncology drug candidate BAL27862 at international cancer conference Basilea presents new research data on ... presents new research data on its innovative antitumor drug candidate BAL27862 at the international conference ... on Molecular Targets and Cancer Therapeutics in Boston (MA). BAL27862 is a novel, intravenous and ...
- Cancer: Studies from Harvard University, Institute for Health Policy update current data on cancer 24 Nov 2009 06:03 GMT
... 'General internist communication about sexual function with cancer survivors.' "Sexual dysfunction is an important issue that ... Policy, Harvard Medical School, 50 Staniford Street, Boston, MA 02114 USA.. is: Springer, 233 Spring ...
- Nereus Pharmaceuticals Presents Positive Interim Data from the ADVANCE Study, a Randomized Phase 2 Clinical Trial of Plinabulin (NPI-2358) in Non-Small Cell Lung Cancer at the 2009 EORTC-NCI-AACR Conf 23 Nov 2009 13:30 GMT
... in patients with advanced non-small cell lung cancer (NSCLC). This data is consistent with the ... Molecular Targets and Cancer Therapeutics meeting in Boston, Massachusetts by the lead author Dr. Rebecca ... needs such as those with squamous cell carcinoma," said Kobi Sethna, President and CEO, Nereus ...
- Nereus Pharmaceuticals Presents Positive Interim Data from the ADVANCE Study, a Randomized Phase 2 Clinical Trial of Plinabulin (NPI-2358) in Non-Small Cell Lung Cancer at the 2009 EORTC-NCI-AACR Conference 23 Nov 2009 14:04 GMT
... of Plinabulin (NPI-2358) in Non-Small Cell Lung Cancer at the 2009 EORTC-NCI-AACR Conference )--Nereus Pharmaceuticals, ... Molecular Targets and Cancer Therapeutics meeting in Boston, Massachusetts by the lead author Dr. Rebecca ... needs such as those with squamous cell carcinoma,” said Kobi Sethna, President and CEO, Nereus ...
- ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Merkel Cell Carcinoma 19 Nov 2009 05:58 GMT
... IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with ... candidate in the treatment of Merkel cell carcinoma (MCC). Meaningful evidence of anticancer activity has ... Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC ...
- Exelixis reports promising data from Phase I study of XL147 in patients with advanced solid tumours 19 Nov 2009 13:58 GMT
... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held 15-19 November in Boston. Michael Morrissey, president of research and development ... trial of XL147. The patient with cervical adenocarcinoma, who experienced a PR, had biomarker reductions ...
- Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer 18 Nov 2009 12:32 GMT
... RNAi Therapeutic for the Treatment of Liver Cancer CAMBRIDGE, Mass. - (BUSINESS WIRE) - Alnylam ... held November 15 - 19, 2009 in Boston, Mass. ALN-VSP is an RNAi therapeutic currently ... the treatment of liver cancers, including hepatocellular carcinoma (HCC) and other solid tumors with liver ...
- New class of drugs nips cancer growth in the bud 26 Nov 2009 05:40 GMT
... class of drugs that practically nips lung cancer regrowth. In pre-clinical trials, it was found ... stays active for a long time, preventing tumour regrowth. The researchers are not sure why ... this new class of anti-cancer drugs in Boston in the US. The drugs are a ...
- New class of drugs nips cancer growth in the bud 26 Nov 2009 19:11 GMT
... class of drugs that practically nips lung cancer regrowth. In pre-clinical trials, it was found ... stays active for a long time, preventing tumour regrowth. The researchers are not sure why ... this new class of anti-cancer drugs in Boston in the US. The drugs are a ...
- Alnylam Presents New Pre-clinical Data On ALN-VSP, An RNAi Therapeutic For The Treatment Of Liver Cancer 20 Nov 2009 09:59 GMT
... presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 ... held November 15 - 19, 2009 in Boston, Mass. ALN-VSP is an RNAi therapeutic currently ... the treatment of liver , including hepatocellular carcinoma (HCC) and other solid tumors with liver ...
Powered by 
Massachusetts Health News Sections
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
nytimes.com:
reuters.com:
wsj.com:
wsj.com:
msnbc.msn.com:
bbc.co.uk: